Salute e Benessere
Systemic Sclerosis Market to Exhibit Significant Growth by 2034, Predicts DelveInsight | Key Companies - Kyowa Hakko Kirin, AstraZeneca, Mitsubishi Tanabe Pharma, Genentech, Amgen, GlaxoSmithKline, Boehringer Ingelheim
Discover which therapies are expected to grab the major systemic sclerosis market share @
Systemic sclerosis, also known as scleroderma, is a chronic autoimmune disease characterized by the hardening and tightening of the skin and connective tissues. The condition arises due to the overproduction and accumulation of collagen in the skin and internal organs, leading to fibrosis. The exact cause of systemic sclerosis is not well understood, but it is believed to involve a combination of genetic predisposition and environmental factors, which trigger an abnormal immune response.
Symptoms of systemic sclerosis vary widely depending on the organs affected and the severity of the disease. Common symptoms include skin thickening and hardening, particularly on the fingers, hands, and face, Raynaud's phenomenon, and joint pain. As the disease progresses, it can affect internal organs, leading to complications such as esophageal dysfunction, pulmonary fibrosis, renal crisis, and heart issues.
Diagnosing systemic sclerosis involves a combination of clinical evaluation, laboratory tests, and imaging studies. A physical examination often reveals characteristic skin changes and blood tests may show specific autoantibodies, such as anti-centromere or anti-topoisomerase I (Scl-70) antibodies. Imaging techniques like high-resolution computed tomography (HRCT) of the lungs and echocardiography can assess the extent of internal organ involvement. A skin biopsy may also be performed to confirm the diagnosis by showing typical histopathological changes associated with the disease.
The systemic sclerosis epidemiology section provides insights into the historical and current systemic sclerosis patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The systemic sclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
While no treatment has been shown to alter the overall progression of the disease, the therapy aims to address specific organ involvement early on to prevent irreversible damage, enhancing both quality of life and survival. Disease-modifying drugs can be recommended based on the clinical presentation and potential visceral damage. Special attention should be given to symptomatic drug treatments. Hematopoietic stem cell transplantation may be an option for patients with rapidly progressing systemic sclerosis who are at risk of organ failure, but it should only be performed at high-volume centers.
The treatment of systemic sclerosis is tailored to address specific manifestations such as skin, lung, gastric, heart, and kidney issues. Most therapies aim to treat the affected organs to prevent irreversible damage and to enhance both quality of life and survival. The primary manifestations of SSc are cutaneous and pulmonary and recommended treatments include Intravenous Cyclophosphamide, Methotrexate, Mycophenolate Mofetil, or Azathioprine. Cyclophosphamide is particularly prescribed for improving skin conditions in patients with SSc-associated interstitial lung disease.
For scleroderma pulmonary fibrosis, antifibrotic therapies like D-penicillamine, Esbriet (pirfenidone), and Ofev (nintedanib) are utilized. Raynaud's phenomenon (RP) and digital ulcers are commonly treated with calcium-channel blockers, phosphodiesterase 5 inhibitors, and angiotensin-converting enzyme inhibitors.
In cases of severe diffuse cutaneous SSc (dcSSc), autologous hematopoietic stem cell transplantation has been shown to improve patient survival, cutaneous symptoms, pulmonary involvement, and overall quality of life.
To know more about systemic sclerosis treatment guidelines, visit @
Some of the drugs in the pipeline include , among others.
is an innovative monoclonal antibody that functions as an Interleukin 17 receptor antagonist, targeting the inflammatory cytokine pathway. It blocks Interleukin 17 interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer, and IL-25. Kyowa Kirin submitted a supplemental New Drug Application (sNDA) to Japan's Ministry of Health, Labour and Welfare (MHLW) in December 2021 , based on Phase III study results in Japanese patients with systemic sclerosis, characterized by moderate to severe skin sclerosis. In June 2022 , the company presented the positive outcomes from this Phase III study at the EULAR (European Alliance of Associations for Rheumatology) 2022 Congress.
, a fully human CD19-CAR T cell investigational therapy that includes a 4-1BB component, is engineered to deplete CD19-positive B cells deeply and temporarily after a single infusion. This approach aims to "reset" the immune system, potentially leading to long-term remission without ongoing therapy for patients with autoimmune diseases. In October 2023 , the US FDA approved the IND application for CABA-201 for a Phase I/II study targeting systemic sclerosis. By March 2024 , the drug was granted an Orphan Drug Designation (ODD) for systemic sclerosis treatment. Additionally, it received Fast Track Designation (FTD) from the US FDA in January 2024 for the same condition. The company has started a Phase I/II open-label study (RESET-SSc) of CABA-201 in systemic sclerosis patients, dividing participants into two parallel cohorts: six patients with severe skin involvement and six patients with pulmonary, cardiac, or renal involvement, regardless of skin condition.
The other therapies in the pipeline include
The anticipated launch of these emerging therapies for systemic sclerosis are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the systemic sclerosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about systemic sclerosis drugs in development @
The dynamics of the systemic sclerosis market are expected to change in the coming years. Based on the role of B cells and the published clinical data with in systemic sclerosis, it is believed that CABA-201 may transform the treatment for systemic sclerosis. submitted an sNDA for in treating systemic sclerosis, and the launch of this drug will boost the systemic sclerosis market. Additionally, the that allows for tracking and predicting the severity and potential progress of the disease, as well as the effectiveness of any therapeutic intervention, is crucial. Since is a leading cause of morbidity and mortality in systemic sclerosis, there is a that can stabilize or improve lung function and delay disease progression.
Furthermore, potential therapies are being investigated for the treatment of systemic sclerosis, and it is safe to predict that the treatment space will significantly impact the systemic sclerosis market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the systemic sclerosis market in the 7MM.
However several factors may impede the growth of the systemic sclerosis market. Only of systemic sclerosis patients are eligible for current treatment, and while has shown benefits mostly in kidney disease and reduction in left ventricular hypertrophy, it has not demonstrated dramatic improvement in outcomes for all organ systems. Additionally, , including limited coverage by healthcare payers or , may limit patient access to expensive SSc therapies.
Moreover, systemic sclerosis treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the systemic sclerosis market growth may be offset by , , , and a . In addition, the about the disease may also impact the systemic sclerosis market growth.
Download the report to understand which factors are driving systemic sclerosis market trends @
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the systemic sclerosis epidemiology trends.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key systemic sclerosis companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diffuse cutaneous systemic sclerosis companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diffuse cutaneous systemic sclerosis companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com